Edition:
United Kingdom

Catalent Inc (CTLT.N)

CTLT.N on New York Stock Exchange

54.30USD
19 Jul 2019
Change (% chg)

$0.01 (+0.02%)
Prev Close
$54.29
Open
$54.29
Day's High
$54.72
Day's Low
$54.22
Volume
142,640
Avg. Vol
219,154
52-wk High
$55.98
52-wk Low
$29.26

Latest Key Developments (Source: Significant Developments)

Catalent Biologics Announces Agreement To Provide Production For Spinal Muscular Atrophy
Tuesday, 16 Jul 2019 

July 16 (Reuters) - Catalent Inc ::CATALENT INC. - CATALENT ANNOUNCES AGREEMENT TO PROVIDE PRODUCTION FOR SPINAL MUSCULAR ATROPHY.CATALENT INC - AVEXIS WILL HAVE DEDICATED MANUFACTURING SPACE AT NEW COMMERCIAL MANUFACTURING CENTER NEAR BALTIMORE-WASHINGTON INTERNATIONAL AIRPORT.CATALENT INC - UNIT TO PROVIDE PROCESS DEVELOPMENT FOR CLINICAL SUPPLY OF ADDITIONAL VIRAL THERAPIES IN AVEXIS PIPELINE.  Full Article

Catalent Extends Global Commercial Spray Drying Capabilities In Europe
Tuesday, 9 Jul 2019 

July 9 (Reuters) - Catalent Inc ::CATALENT EXTENDS GLOBAL COMMERCIAL SPRAY DRYING CAPABILITIES IN EUROPE.CATALENT INC - EXPANDED CAPACITY OF GLOBAL SPRAY DRYING OPERATIONS THROUGH AGREEMENT WITH SANOFI ACTIVE INGREDIENT SOLUTIONS.CATALENT - UNDER AGREEMENT SANOFI TO PROVIDE CO ACCESS TO SPRAY DRYING MANUFACTURING SERVICES FOR CO'S CUSTOMERS AT SANOFI'S HAVERHILL, U.K. FACILITY.  Full Article

Catalent To Buy Gene Therapy Leader Paragon Bioservices For $1.2Bln
Monday, 15 Apr 2019 

April 15 (Reuters) - Catalent Inc ::CATALENT TO ACQUIRE GENE THERAPY LEADER PARAGON BIOSERVICES, INC. FOR $1.2 BILLION.CATALENT TO ACQUIRE GENE THERAPY LEADER PARAGON BIOSERVICES, INC. FOR $1.2 BILLION.CATALENT INC - PARAGON IS EXPECTED TO ACHIEVE MORE THAN $200 MILLION IN REVENUE IN CALENDAR YEAR 2019.CATALENT INC - CATALENT EXPECTS TRANSACTION TO BE ACCRETIVE TO ITS ADJUSTED NET INCOME PER SHARE IN SECOND FULL FISCAL YEAR AFTER CLOSING.CATALENT INC - CATALENT INTENDS TO FUND TRANSACTION WITH PROCEEDS OF A $650 MILLION INCREMENTAL TERM LOAN.CATALENT INC - DEFINITIVE MERGER AGREEMENT FOR ACQUISITION CONTEMPLATES AN ALL-CASH PURCHASE OF ALL OF PARAGON'S OUTSTANDING EQUITY.CATALENT INC - CATALENT INTENDS TO FUND TRANSACTION WITH ISSUANCE OF $650 MILLION OF A NEW SERIES OF CONVERTIBLE PREFERRED STOCK.CATALENT INC - UPON COMPLETION OF TRANSACTION, PARAGON'S ENTIRE ORGANIZATION WILL REMAIN UNDER LEADERSHIP OF PETE BUZY.CATALENT INC - ACQUISITION CONTEMPLATES AN ALL-CASH PURCHASE OF ALL OF PARAGON'S OUTSTANDING EQUITY FOR $1.2 BILLION ON A CASH-FREE, DEBT-FREE BASIS.CATALENT INC - PETER ZIPPELIUS, A PARTNER AT LGP, WILL JOIN CATALENT'S BOARD OF DIRECTORS.CATALENT - AT JUNE 30, AFTER EXPECTED CLOSING OF ACQUISITION AND RELATED FINANCINGS, PRO FORMA NET LEVERAGE RATIO IS EXPECTED TO BE ABOUT 4.0X.CATALENT INC - CATALENT WILL USE FUNDS REMAINING FROM FINANCINGS TO PAY PORTION OF COSTS OF CAPITAL EXPANSION PROJECTS CURRENTLY UNDERWAY IN MARYLAND.  Full Article

Contract Drug Manufacturer Catalent To Buy Paragon Bioservices In $1.2 Billion Deal - WSJ
Sunday, 14 Apr 2019 

April 14 (Reuters) - :CONTRACT DRUG MANUFACTURER CATALENT TO BUY PARAGON BIOSERVICES IN $1.2 BILLION DEAL - WSJ.  Full Article

Catalent Announces Public Offering Of 9.94 Mln Common Shares Priced At $40.24 Per Share
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Catalent Inc ::CATALENT, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING OF 9.94 MILLION COMMON SHARES PRICED AT $40.24PER SHARE.  Full Article

Catalent Announces Public Offering Of Common Stock
Monday, 23 Jul 2018 

July 23 (Reuters) - Catalent Inc ::CATALENT, INC. ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.CATALENT INC - ANNOUNCED THAT IT HAS LAUNCHED AN UNDERWRITTEN PUBLIC OFFERING OF $400.0 MILLION OF ITS COMMON STOCK.CATALENT INC - INTENDS TO USE NET PROCEEDS OF OFFERING TO REPAY A PORTION OF OUTSTANDING BORROWINGS UNDER ITS U.S. DOLLAR-DENOMINATED TERM LOANS.  Full Article

Juniper Pharma To Pay Catalent Termination Fee Of $5.58 Mln Under Certain Circumstances
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Catalent Inc ::JUNIPER PHARMACEUTICALS SAYS UPON TERMINATION OF MERGER UNDER CERTAIN CIRCUMSTANCES, CO TO PAY CATALENT TERMINATION FEE OF $5.580 MILLION - SEC FILING.  Full Article

Juniper Pharmaceuticals Says Signs Definitive Agreement To Be Acquired By Catalent For $11.50 Per Share In Cash
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Juniper Pharmaceuticals Inc ::JUNIPER PHARMACEUTICALS SIGNS DEFINITIVE AGREEMENT TO BE ACQUIRED BY CATALENT, INC. FOR $11.50 PER SHARE IN CASH.JUNIPER PHARMACEUTICALS - DEFINITIVE AGREEMENT WITH CATALENT FOR CATALENT TO BUY ALL OF OUTSTANDING SHARES OF CO AT $11.50 PER SHARE IN CASH.TRANSACTION REPRESENTS A TOTAL EQUITY VALUE OF APPROXIMATELY $139.6 MILLION ON A FULLY-DILUTED BASIS.TRANSACTION APPROVED UNANIMOUSLY BY JUNIPER BOARD OF DIRECTORS.ROTHSCHILD & CO IS ACTING AS FINANCIAL ADVISOR AND GOODWIN PROCTER LLP IS ACTING AS LEGAL COUNSEL TO JUNIPER.  Full Article

Catalent Signs Agreement To Acquire Juniper Pharmaceuticals
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Catalent Inc ::CATALENT SIGNS AGREEMENT TO ACQUIRE JUNIPER PHARMACEUTICALS, INC..CATALENT INC -UNDER ACQUISITION AGREEMENT WITH JUNIPER, CO'S SUBSIDIARY TO COMMENCE TENDER OFFER TO PURCHASE ALL OF JUNIPER'S SHARES FOR PRICE OF $11.50.CATALENT INC SAYS CATALENT WILL CONTINUE TO SUPPORT JUNIPER'S CRINONE FRANCHISE MARKETED BY MERCK KGAA OUTSIDE OF U.S..CATALENT INC-AFTER TENDER OFFER, CO INTENDS TO COMPLETE DEAL BY BUYING REMAINDER JUNIPER SHARES AT SAME PRICE THROUGH MERGER WITH NEWLY FORMED UNIT OF CO.  Full Article

Catalent Q1 earnings per share $0.03
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Catalent Inc ::Catalent Inc. Reports first quarter fiscal 2018 results.Q1 earnings per share $0.03.Sees FY 2018 revenue $2.31 billion to $2.41 billion.Q1 revenue $543.9 million versus I/B/E/S view $491 million.Q1 earnings per share view $0.17 -- Thomson Reuters I/B/E/S.Q1 adjusted non-gaap earnings per share $0.21.Catalent - ‍expects fiscal year 2018 adjusted EBITDA in range of $521 million to $547 million and adjusted net income in range of $198 million to $224 million​.Catalent - ‍company expects self-funded capital expenditures in range of $152 million to $165 million for FY2018 ​.Catalent - ‍expects self-funded capital expenditures in range of $152 million to $165 million for fiscal year 2018​.Fy2018 revenue view $2.31 billion -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Catalent Biologics Announces Agreement To Provide Production For Spinal Muscular Atrophy

* CATALENT INC. - CATALENT ANNOUNCES AGREEMENT TO PROVIDE PRODUCTION FOR SPINAL MUSCULAR ATROPHY